16 recruiting, 3 not yet recruiting, 1 enrolling by invitation, 1 terminated. 12 Phase 2, 10 Phase 1, 2 Early Phase 1, 2 Phase 3, 1 Not applicable.
Follow Small Cell Lung Cancer ( SCLC ): new trials by email Literature Review of Small Cell Lung Cancer ( SCLC ) trials Research Report on Small Cell Lung Cancer ( SCLC )
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer Lurbinectedin, Osimertinib - Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Misty Shields | 16 | 2027-01-01 | 2026-10-15 |
| Prospective Multiomic Analysis in Small-Cell Lung Cancer Biospecimen collection - Small Cell Cancer Of The Lung, Small Cell Lung Cancer ( SCLC ) | Recruiting | Ohio State University Comprehensive Cancer Center | 30 | 2026-11-25 | 2026-10-02 | |
| A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) Alisertib, Paclitaxel - Small Cell Lung Cancer ( SCLC ) | Phase 2 | Recruiting | Puma Biotechnology, Inc. | 50 | 2026-09-17 | 2026-10-28 |
| A Study of Armored CAR T Cells in People With Cancer DLL3-SAVVYZ-IL18 CAR T cell - Neuroendocrine Cancer, Small Cell Lung Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 16 | 2026-08-28 | 2026-10-22 |
| TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors TLN-499, Venetoclax - Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer | Phase 1 | Recruiting | Treeline Biosciences, Inc. | 120 | 2026-08-05 | 2026-10-01 |
| A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for Elderly Patients With Small-cell Lung Cancer or Those Who Are Intolerant to Intensive Chemotherapy benmelstobart in combination with anlotinib and etoposide - Small Cell Lung Cancer ( SCLC ) | Phase 3 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 64 | 2026-08-01 | 2026-07-27 |
| Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic) IDP-121 - Small Cell Lung Cancer ( SCLC ) | Phase 1 / Phase 2 | Recruiting | IDP Discovery Pharma S.L. | 60 | 2026-07-28 | 2026-10-07 |
| Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer PF-08634404, Chemotherapy - Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ) | Phase 2 | Recruiting | Pfizer | 40 | 2026-07-02 | 2026-10-09 |
| TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC TC-D101 CAR-T - Small Cell Lung Cancer ( SCLC ), CAR-T Cell Therapy | Early Phase 1 | Recruiting | TCRCure Biopharma Ltd. | 24 | 2026-06-10 | 2026-10-26 |
| Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Sacituzumab govitecan, Atezolizumab, Durvalumab - Small Cell Lung Cancer ( SCLC ), Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | Recruiting | Bindu R Potugari | 35 | 2026-05-14 | 2026-07-28 |
| DLL3-Targeted PET/CT in Small Cell Lung Cancer conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT - PET/CT, Small Cell Lung Cancer ( SCLC ) | Not applicable | Recruiting | The First Affiliated Hospital of Xiamen University | 20 | 2026-05-09 | 2026-07-01 |
| Establishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment radiatherapy, and chemotherapy with or without immunotherapy as clinical practice - Small Cell Lung Cancer ( SCLC ), Radiotherapy | Recruiting | Shanghai Chest Hospital | 500 | 2026-04-01 | 2026-05-04 | |
| 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer Sequential [18F]-FDG PET/CT, [68Ga]Ga-PFD3 PET/CT scan - SCLC, SCLC, Extensive Stage | Phase 1 / Phase 2 | Recruiting | Peking University First Hospital | 30 | 2025-10-22 | 2026-06-18 |
| Penfluridol for Relapsed/Refractory Small Cell Cancers Penfluridol Monotherapy for Relapsed/Refractory Small-Cell Lung or Cervical Cancer - Small Cell Carcinoma, Small Cell Carcinoma of Lung | Phase 1 / Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 33 | 2025-10-01 | 2025-10-03 |
| A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC) Small Cell Lung Cancer ( SCLC ), Lambert Eaton Myasthenic Syndrome (LEMS) | Withdrawn | Addario Lung Cancer Medical Institute | 2025-09-01 | 2026-08-04 | ||
| Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors CP-383 - Solid Tumor Malignancies, Colorectal Carcinoma | Phase 1 / Phase 2 | Recruiting | Tasca Therapeutics | 150 | 2025-08-27 | 2026-02-18 |
| Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer Organoid Drug Sensitivity Testing-Guided Therapy, Topotecan - Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive-stage Small Cell Lung Cancer (SCLC) | Phase 2 / Phase 3 | Not yet recruiting | Peking Union Medical College Hospital | 128 | 2025-08-01 | 2025-08-06 |
| A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products No additional intervention administered in this long term follow-up study - Solid Tumor Cancer, Solid Tumor, Unspecified, Adult | Enrolling by invitation | A2 Biotherapeutics Inc. | 400 | 2025-07-31 | 2026-05-20 | |
| 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors 177Lu-RAD204 - PDL1 Gene Mutation, Non Small Cell Lung Cancer | Early Phase 1 | Recruiting | Radiopharm Theranostics, Ltd | 30 | 2024-06-03 | 2026-02-19 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) rezatapopt, pembrolizumab - Advanced Solid Tumor, Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | PMV Pharmaceuticals, Inc | 300 | 2020-10-29 | 2026-10-02 |
Showing 20 of 22. Sign in to see all of them.
Small Cell Lung Carcinoma (22) · Lung Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Squamous Cell Carcinoma of Head and Neck (4) · Colorectal Neoplasms (3) · Head and Neck Neoplasms (3) · Neoplasm Metastasis (3) · Pancreatic Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Carcinoma, Neuroendocrine (2) · Endometrial Neoplasms (2) · Mesothelioma (2) · Ovarian Neoplasms (2) · Recurrence (2) · Breast Neoplasms (1)
Bronchial Neoplasms (22) · Carcinoma, Bronchogenic (22) · Lung Diseases (22) · Neoplasms (22) · Neoplasms by Site (22) · Respiratory Tract Diseases (22) · Respiratory Tract Neoplasms (22) · Thoracic Neoplasms (22) · Lung Neoplasms (16) · Carcinoma (7) · Neoplasms by Histologic Type (7) · Neoplasms, Glandular and Epithelial (7) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Adenocarcinoma (4)
Drug Therapy (2) · Etoposide (2) · atezolizumab (2) · pembrolizumab (2) · Carboplatin (1) · Combined Modality Therapy (1) · Cyclophosphamide (1) · Immunotherapy (1) · MLN 8237 (1) · Magnetic Resonance Imaging (1) · PM 01183 (1) · Paclitaxel (1) · Penfluridol (1) · Tablets (1) · Topotecan (1)
A2 Biotherapeutics Inc. (1) · Addario Lung Cancer Medical Institute (1) · Bindu R Potugari (1) · Giuseppe Giaccone (1) · IDP Discovery Pharma S.L. (1) · Memorial Sloan Kettering Cancer Center (1) · Misty Shields (1) · Ohio State University Comprehensive Cancer Center (1) · PMV Pharmaceuticals, Inc (1) · Peking Union Medical College Hospital (1) · Peking University First Hospital (1) · Pfizer (1) · Puma Biotechnology, Inc. (1) · Radiopharm Theranostics, Ltd (1) · Shanghai Chest Hospital (1)
United States (11) · China (6) · Australia (4) · Spain (4) · France (3) · Italy (2) · Brazil (1) · Germany (1) · Hong Kong (1) · India (1) · Israel (1) · Japan (1) · Puerto Rico (1) · Singapore (1) · South Korea (1)
Adam Schoenfeld, MD (1) · Asrar Alahmadi, MBBS, MAS-CR (1) · Eric Ng, MD (1) · Gilbert Youssef, MD (1) · Jacob Sands, MD (1) · Marc Fellous, MD (1) · Misty D Shields, MD, PhD (1) · Padma Yerramilli-Rao, MB BS, PhD (1) · Peng Wu, PhD (1)
PMID 40543428, PMID 40932470, PMID 41740031
2025 (1), R01CA303470 (1)